Korea Pharma Co (XKRX:032300) ROCE % : 4.67% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Korea Pharma Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Korea Pharma Co's annualized ROCE % for the quarter that ended in Dec. 2024 was 4.67%.

Korea Pharma Co ROCE % Historical Data

The historical data trend for Korea Pharma Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Korea Pharma Co ROCE % Chart

Korea Pharma Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

10.04

7.91

2.53

7.70

7.50

Korea Pharma Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-4.69	9.65	8.46	7.12	4.67

Korea Pharma Co ROCE % Calculation

Korea Pharma Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	6786.199	/	( ( (121303.373 - 33299.954)	+	(112386.95 - 19320.752) )	/ 2 )
	=	6786.199	/	( (88003.419	+	93066.198)	/ 2 )
	=	6786.199	/	90534.8085
	=	7.50 %

Korea Pharma Co's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	4357.772	/	( ( (111501.843 - 18062.448)	+	(112386.95 - 19320.752) )	/ 2 )
	=	4357.772	/	( ( 93439.395	+	93066.198 )	/ 2 )
	=	4357.772	/	93252.7965
	=	4.67 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Korea Pharma Co (XKRX:032300) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Korea Pharma Co ROCE % Related Terms

Thank you for viewing the detailed overview of Korea Pharma Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Korea Pharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Korea Pharma Co Ltd (XKRX:032300) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

8th Floor, 14, Teheran-ro 4-gil, Gangnam-gu, Seoul, KOR

Website

http://www.koreapharma.co.kr

Korea Pharma Co Ltd is a drug manufacturer. The company's products include amino acid drugs; antibiotic drugs; antidotal drugs; antiepileptic drugs; antihistamine drugs; anti-inflammatory drugs; antimicrobial drugs; antiplatelet drugs; circulatory system drugs; cns drugs; dermatological drugs; endocrine drugs; gastrointestinal drugs; hepatic drugs; hormonal drugs; multivitamins; respiratory drugs; skeltal muscle relaxants; specialty drugs; sympathomimetic drugs; and vitamin b1.

Korea Pharma Co Headlines

No Headlines